Clinical Trials Directory

Trials / Completed

CompletedNCT00369109

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

Collection of Skin Biopsy With Hair Follicles as Surrogate to Develop Biomarker Assays From Patients With Advanced Solid Tumor Malignancies Receiving Either Single Agent Weekly Irinotecan or Gemcitabine

Status
Completed
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
Barbara Ann Karmanos Cancer Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is collecting skin biopsy specimens from patients receiving irinotecan or gemcitabine for advanced solid tumors and using them to study change in DNA due to this treatment.

Detailed description

OBJECTIVES: Primary * Determine the level of p-Chk1 and phospho-histone 2AX (p-H2AX), an indicator of DNA damage, and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors. Secondary * Characterize the method for measurement (immunohistochemistry). * Measure inter- and intra-patient variability for the biomarker. * Partially characterize the dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent. OUTLINE: This is a multicenter study. Patients undergo collection of 2 skin biopsies with hair follicles at 4 and 8 hours or at 4 and 6 hours after the start of irinotecan hydrochloride or gemcitabine hydrochloride treatment on day 1 of course 1. Repeat biopsies will be taken at 4, 6, or 8 hours after the start of irinotecan hydrochloride or gemcitabine hydrochloride on day 1 of 2 successive courses. Tissue is examined by immunohistochemistry and possibly other methods for changes in p-Chk1 and pH2AX. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
OTHERbiologic sample preservation procedure
OTHERimmunohistochemistry staining method
OTHERlaboratory biomarker analysis
PROCEDUREbiopsy

Timeline

Start date
2006-02-01
Primary completion
2006-11-01
Completion
2007-06-01
First posted
2006-08-29
Last updated
2013-04-08

Locations

2 sites across 2 countries: United States, United Kingdom

Source: ClinicalTrials.gov record NCT00369109. Inclusion in this directory is not an endorsement.